cs.CVOct 24, 2026

How Robust Are CNNs and Vision Transformers for Alzheimer's MRI Classification Across Datasets?

Authors: Hafija Aktar, Molly Croes, Frank S. Menniti, Abdeltawab Hendawi

Organizations: Department of Computer Science, University of Rhode Island, Kingston, RI 02881, USA · Department of Biomedical and Pharmaceutical Sciences, George & Anne Ryan Institute for Neuroscience, University of Rhode Island, Kingston, RI 02881, USA

Abstract

Accurate assessment of Alzheimer's disease stages from MRI is important for understanding disease progression and supporting the development of computer-aided analysis tools. Deep learning models have shown promising results for Alzheimer's disease classification from MRI. However, when evaluated on single datasets, it is difficult to determine whether the observed performance reflects consistent architectural behavior or dataset-specific effects. In this work, we present a multi-dataset benchmarking framework with standardized preprocessing and evaluation. We compare five architectures: ResNet-50, ReXNet-150, Swin Transformer, ViT-Base, and ViT-Large. The models are evaluated across three MRI datasets representing severe class imbalance, train-test distribution mismatch, and large-scale augmentation. The results show broadly consistent performance patterns across datasets, with ViT-Large achieving the best performance on all three datasets and reaching up to 99.84% accuracy and 99.86% macro F1. Performance differences between architectures are most pronounced under distribution mismatch and considerably smaller in the augmented-data setting. Across datasets, lower class-level performance is observed primarily among adjacent early-stage categories, particularly Very Mild and Mild impairment. These findings highlight the importance of evaluating deep learning architectures across multiple data conditions rather than relying on single-dataset performance.

Figures & tables

Explore similar work

Aug 12, 2026

A comparison of CNN architectures for Alzheimer's disease detection in single-view MRI scans

Alzheimer's disease is a leading cause of death with no cure. Therefore, early detection is critical to slow progression and preserve quality of life. Diagnosis relies on medical history, cognitive tests, physical exams, and MRI brain scans, making deep learning suitable for Alzheimer's classification. This work proposes a benchmark that evaluates ten different convolutional neural network (CNN) architectures (including ResNet, DenseNet, MobileNet, EfficientNet, and VGG family models) under the same held-out test split protocol. A two-stage transfer learning and full fine-tuning pipeline is introduced to perform training using a class-balanced subset (3,900 images) derived from the OASIS medical imaging dataset, comprising 86,437 single-view MRI brain scans labeled into four classifications of Alzheimer's disease: Non-Demented, Very Mild Dementia, Mild Dementia, and Moderate Dementia. The best results were achieved by VGG16, with a 0.9637 validation accuracy and a 0.9533 test accuracy score. A key finding documented in this work is the difficulty of classifying the transition from Non-Demented to Very Mild Demented stages, observed consistently across all ten architectures.
Feb 28, 2026

Multiple Inputs and Mixwd data for Alzheimer's Disease Classification Based on 3D Vision Transformer

The current methods for diagnosing Alzheimer Disease using Magnetic Resonance Imaging (MRI) have significant limitations. Many previous studies used 2D Transformers to analyze individual brain slices independently, potentially losing critical 3D contextual information. Region of interest-based models often focus on only a few brain regions despite Alzheimer's affecting multiple areas. Additionally, most classification models rely on a single test, whereas diagnosing Alzheimer's requires a multifaceted approach integrating diverse data sources for a more accurate assessment. This study introduces a novel methodology called the Multiple Inputs and Mixed Data 3D Vision Transformer (MIMD-3DVT). This method processes consecutive slices together to capture the feature dimensions and spatial information, fuses multiple 3D ROI imaging data inputs, and integrates mixed data from demographic factors, cognitive assessments, and brain imaging. The proposed methodology was experimentally evaluated using a combined dataset that included the Alzheimer's Disease Neuroimaging Initiative (ADNI), the Australian Imaging, Biomarker, and Lifestyle Flagship Study of Ageing (AIBL), and the Open Access Series of Imaging Studies (OASIS). Our MIMD-3DVT, utilizing single or multiple ROIs, achieved an accuracy of 97.14%, outperforming the state-of-the-art methods in distinguishing between Normal Cognition and Alzheimer's Disease.
Oct 23, 2026

EigenGradCAM with AugSmooth: Enhancing Explainability and Precision in Multi-Stage Alzheimer's Disease Detection

Alzheimer's disease (AD) is a progressive neurological disorder associated with memory loss, cognitive decline, and behavioral disturbances. Early and accurate diagnosis is essential, yet MRI-based deep learning models often lack interpretability, limiting their clinical use. This study presents an explainable deep learning approach for four-class AD staging using 2D axial MRI images. The method combines eigenvector-based Grad-CAM with gradient smoothing to improve saliency localization and heatmap stability. Principal component analysis is applied to gradient-weighted convolutional layers, while Gaussian noise is added to saliency weights before decomposition. To address class imbalance in the Moderate Dementia category, Wasserstein Generative Adversarial Network with Gradient Penalty (WGAN-GP) generates synthetic samples to balance the four-stage training distribution. Custom convolutional neural networks are trained on the Best Alzheimer MRI Dataset, achieving 97.2% test accuracy, 97.0% balanced accuracy, and a Matthews correlation coefficient of 0.944. The area under the ROC curve ranges from 0.96 to 0.99 across classes. Generated heatmaps highlight the hippocampus and entorhinal cortex, regions associated with Alzheimer's disease biomarkers. These findings suggest that the proposed approach combines strong classification performance with improved model interpretability, although further clinical validation is needed.